Claudia Coscia1, Ana Jaureguizar2, Carlos Andres Quezada2, Alfonso Muriel3, Manuel Monreal4, Tomas Villén5, Esther Barbero2, Diana Chiluiza2, Roger D Yusen6, David Jimenez2. 1. Biostatistics Department, Ramón y Cajal Hospital and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, CIBERESP, Madrid, Spain. 2. Respiratory Department, Hospital Ramón y Cajal, Medicine Department, Universidad de Alcala (IRYCIS), Madrid, Spain. 3. Biostatistics Department, Ramón y Cajal Hospital and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, CIBERESP, Madrid, Spain. Electronic address: alfonso.muriel@hrc.es. 4. Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Universidad Católica de Murcia, Murcia, Spain. 5. Emergency Department, Hospital Universitario La Paz, Madrid, Spain. 6. Divisions of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, MO.
Abstract
BACKGROUND: It is unknown whether propensity score-adjusted observational studies produce results comparable to those of randomized controlled trials (RCTs) that address similar VTE treatment issues. METHODS: The PubMed and Web of Science databases were systematically searched for propensity score-adjusted observational studies, RCTs, and meta-analyses of RCTs that estimated all-cause mortality following VTE treatment. After identifying distinct clinical treatment issues evaluated in the eligible observational studies, a standardized algorithm was used to identify and match at least one RCT or RCT meta-analysis publication for paired study design analyses. Meta-analyses were used to summarize groups of studies. Treatment efficacy statistics (relative ORs) were compared between the paired observational and RCT studies, and the summary relative ORs for all study design pairs were also calculated. RESULTS: The observational and RCT study pairs assessed seven clinical treatment issues. Overall, the observational study-RCT pairs did not exhibit significantly different mortality estimates (summary relative OR, 0.89; 95% CI, 0.32-1.46; I2 = 23%). However, two of the seven treatment issue study pairs (thrombolysis vs anticoagulation for pulmonary embolism; once- vs twice-daily enoxaparin for VTE) exhibited a significantly different treatment effect direction, and there was a substantial (nonsignificant) difference in the magnitude of the effect in another two of the study pairs (rivaroxaban vs vitamin K antagonists for VTE; home treatment vs hospitalization for DVT). CONCLUSIONS: This systematic comparison across seven VTE treatment topics suggests that propensity score-adjusted observational studies and RCTs often exhibit similar all-cause mortality, although differences in the direction or the magnitude of estimated treatment effects may occasionally occur. TRIAL REGISTRY: PROSPERO; CRD42018087819; URL: http://www.crd.york.ac.uk/PROSPERO.
BACKGROUND: It is unknown whether propensity score-adjusted observational studies produce results comparable to those of randomized controlled trials (RCTs) that address similar VTE treatment issues. METHODS: The PubMed and Web of Science databases were systematically searched for propensity score-adjusted observational studies, RCTs, and meta-analyses of RCTs that estimated all-cause mortality following VTE treatment. After identifying distinct clinical treatment issues evaluated in the eligible observational studies, a standardized algorithm was used to identify and match at least one RCT or RCT meta-analysis publication for paired study design analyses. Meta-analyses were used to summarize groups of studies. Treatment efficacy statistics (relative ORs) were compared between the paired observational and RCT studies, and the summary relative ORs for all study design pairs were also calculated. RESULTS: The observational and RCT study pairs assessed seven clinical treatment issues. Overall, the observational study-RCT pairs did not exhibit significantly different mortality estimates (summary relative OR, 0.89; 95% CI, 0.32-1.46; I2 = 23%). However, two of the seven treatment issue study pairs (thrombolysis vs anticoagulation for pulmonary embolism; once- vs twice-daily enoxaparin for VTE) exhibited a significantly different treatment effect direction, and there was a substantial (nonsignificant) difference in the magnitude of the effect in another two of the study pairs (rivaroxaban vs vitamin K antagonists for VTE; home treatment vs hospitalization for DVT). CONCLUSIONS: This systematic comparison across seven VTE treatment topics suggests that propensity score-adjusted observational studies and RCTs often exhibit similar all-cause mortality, although differences in the direction or the magnitude of estimated treatment effects may occasionally occur. TRIAL REGISTRY: PROSPERO; CRD42018087819; URL: http://www.crd.york.ac.uk/PROSPERO.
Authors: Issa J Dahabreh; Radley C Sheldrick; Jessica K Paulus; Mei Chung; Vasileia Varvarigou; Haseeb Jafri; Jeremy A Rassen; Thomas A Trikalinos; Georgios D Kitsios Journal: Eur Heart J Date: 2012-06-17 Impact factor: 29.983
Authors: Michael R Jaff; M Sean McMurtry; Stephen L Archer; Mary Cushman; Neil Goldenberg; Samuel Z Goldhaber; J Stephen Jenkins; Jeffrey A Kline; Andrew D Michaels; Patricia Thistlethwaite; Suresh Vedantham; R James White; Brenda K Zierler Journal: Circulation Date: 2011-03-21 Impact factor: 29.690
Authors: H Decousus; A Leizorovicz; F Parent; Y Page; B Tardy; P Girard; S Laporte; R Faivre; B Charbonnier; F G Barral; Y Huet; G Simonneau Journal: N Engl J Med Date: 1998-02-12 Impact factor: 91.245
Authors: Pablo Javier Marchena; José Antonio Nieto; María Guil; Ferrán García-Bragado; Ramón Rabuñal; Henri Boccalon; Javier Trujillo-Santos; Manuel Monreal Journal: Thromb Haemost Date: 2011-11-24 Impact factor: 5.249
Authors: Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores Journal: Chest Date: 2016-01-07 Impact factor: 9.410
Authors: Raffaele Pesavento; Maria Amitrano; Javier Trujillo-Santos; Pierpaolo Di Micco; Sara Mangiacapra; Luciano López-Jiménez; Conxita Falgá; Fernando García-Bragado; Chiara Piovella; Paolo Prandoni; Manuel Monreal Journal: Thromb Res Date: 2014-12-13 Impact factor: 3.944
Authors: Javier Trujillo-Santos; Sebastian Schellong; Conxita Falga; Vanessa Zorrilla; Pedro Gallego; Manuel Barrón; Manuel Monreal Journal: Am J Med Date: 2013-03-14 Impact factor: 4.965
Authors: Min Jun; Lisa M Lix; Madeleine Durand; Matt Dahl; J Michael Paterson; Colin R Dormuth; Pierre Ernst; Shenzhen Yao; Christel Renoux; Hala Tamim; Cynthia Wu; Salaheddin M Mahmud; Brenda R Hemmelgarn Journal: BMJ Date: 2017-10-17